To browse Academia. Background: Lung cancer is one of the most appalling diagnoses, associated with significant patient distress, poured quality of life and often limited survival. Moreover, the current literature emphasizes the effect of distress level on survival rates. The purpose of this study was to explore the survival curve, considering the distress level reported by patients with advanced NSCLC cancer at the beginning of the treatment.
Survival was calculated from time of the histopathological diagnosis. The data was analyzed with descriptive evaluation, followed by Kaplan-Meier models, to test associations with survival and distress.
:max_bytes(150000):strip_icc()/lymphaticdrainagemassage-6f8c7c4b441d4097a594e7cf181f2b0a.png "SEX AGENCY Creil")
Results: Of those patients, The survival rate was Half of patients The most problems reported at PL were worry Conclusion: Despite the limited sample size, the data suggest that mild distress is a prognostic factor in survival rate. The high prevalence of patients with moderate to severe distress, as well as, the problems-related distress, highlighted the importance of the distress screening and also to create an advanced care planning for patients with lung cancer, from the time of diagnosis until the last phase of illness, helping them to cope with this reality.
More studies are thus needed to investigate the implication of distress level at diagnosis as a prognostic factor, increasing and diversifying the sample in order to make the data more generalizable. Introduction: Lung cancer is the leading cause of cancer mortality worldwide, despite advances in management, especially with targeted agents and immunotherapy. Numerous oncogenes have been identified that control the growth of these malignancies.
Anaplastic lymphoma kinase ALK is a tyrosine kinase that develops distorted functioning as a result of chromosomal rearrangement. Patients and methods: In this chart review, we compiled data from two cancer hospitals in Kuwait and Saudi Arabia which were collected from patients with advanced NSCLC treated between January and September with crizotinib after diagnosed with ALK-positive disease.
